drugset / Trial / NCT07172204
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2027-07-31
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 20 mg | Subcutaneous |
| Subject | Homoharringtonine | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |